Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody

References

• Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35:103–10
   PubMed Web of Science ®Google Scholar
• Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1–8
   PubMed Web of Science ®Google Scholar
• Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363–70
   PubMed Web of Science ®Google Scholar
• Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Nat Acad Sci USA 2000;97:5255–60
   PubMed Web of Science ®Google Scholar
• Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9:458–62
   PubMed Web of Science ®Google Scholar
• Unruh D, Turner K, Srinivasan R, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer 2014;134:9–20
   PubMed Web of Science ®Google Scholar
• Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535–45
   PubMed Web of Science ®Google Scholar
• Zucker S, Mirza H, Conner CE, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998;75:780–6
   PubMed Web of Science ®Google Scholar
• Mechtcheriakova D, Wlachos A, Holzmuller H, et al. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999;93:3811–23
   PubMed Web of Science ®Google Scholar
• Armesilla AL, Lorenzo E, Gomez del Arco P, et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol 1999;19:2032–43
   PubMed Web of Science ®Google Scholar
• Bode M, Mackman N. Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player. Vascul Pharmacol 62:57–62
   Google Scholar
• Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor in glioma. Noshuyo Byori 1996;13:115–18
   PubMedGoogle Scholar
• Yu JL, May L, Lhotak V, Shahrzad S, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734–41
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Kakkar AK, Tuddenham EG, et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998;58:4461–7
   PubMed Web of Science ®Google Scholar
• Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870–5
   PubMed Web of Science ®Google Scholar
• Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209–15
   PubMed Web of Science ®Google Scholar
• Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer; immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor. Amer J Pathol 1998;152:399–441
   PubMed Web of Science ®Google Scholar
• Shoji M, Sun A, Kisiel W, et al. Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target 2008;16:185–97
   PubMed Web of Science ®Google Scholar
• Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chloromethyl ketones. J Biol Chem 1989;264:7536–45
   PubMed Web of Science ®Google Scholar
• Sorensen BB, Persson E, Freskgard PO, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997;272:11863–8
   PubMed Web of Science ®Google Scholar
• Sun A, Shoji M, Snyder JP, Liotta DC. Synthesis of EF24-tripeptide-chloromethy ketone: A novel anti-cancer drug delivery system. J Med Chem 2006;49:3153–8
   PubMed Web of Science ®Google Scholar
• Ndungu JM, Lu YJ, Zhu S, et al. Targeted delivery of paclitaxel to tumor cells: Synthesis and in vitro evaluation. J Med Chem 2010;53:3127–32
   PubMed Web of Science ®Google Scholar
• Zhu S, Walter Kisiel W, Lu YJ, et al. Tumor angiogenesis therapy using targeted delivery of paclitaxel to the vasculature of breast cancer metastases. J. Drug Delivery 2014; (in press)
   Google Scholar
• Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001;41:880–5
   PubMed Web of Science ®Google Scholar
• Soderstrom T, Hedner U, Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vascular Surg 2001;33:1072–9
   PubMed Web of Science ®Google Scholar
• Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663–8
   PubMed Web of Science ®Google Scholar
• Yang L, Clarke MJ, Carlson BL, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 2008;14:3993–4001
   Google Scholar
• Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320–7
   PubMed Web of Science ®Google Scholar
• Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005;25:1545–50
   PubMed Web of Science ®Google Scholar
• Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991;66:529–33
   PubMed Web of Science ®Google Scholar
• Salatti JA, Anton P, Nemerson Y, Sakariassen KS. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val. Experiments with flowing non-anticoagulated human blood. Blood Coagul Fibrinolysis 1993;4:881–90
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan R, Hedner U, Ghosh S, et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010;8:301–10
   PubMed Web of Science ®Google Scholar
• Ogawa M, Regino CAS, Choyke PL, Kobayashi H. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther 2009;8:232–9
   PubMed Web of Science ®Google Scholar
• Hue JJ, Lee HJ, Jon S, et al. Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice. J Vet Sci 2013;14:473–9
   PubMed Web of Science ®Google Scholar